First look: new cancer drug tested in china for Tough-to-Treat tumors
NCT ID NCT05382364
Summary
This early-stage study aims to check the safety and understand how the body processes the drug tucatinib in a small group of Chinese patients. It includes people with advanced breast, stomach, or colorectal cancers that have a specific marker called HER2+ and have stopped responding to standard treatments. The main goal is to see how well the drug is tolerated and how it behaves in the body, which is a first step before testing if it can help control these cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 201321, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hunan Cancer Hospital
Changsha, Hunan, 421000, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Conditions
Explore the condition pages connected to this study.